Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials
Author:
Affiliation:
1. Institute of Hematology; Davidoff Cancer Center; Petah Tikva Israel
2. Medicine A, Rabin Medical Center; Petah-Tikva Israel
3. Sackler School of Medicine; Tel Aviv Israel
4. Department of Hematology; Assuta Medical Centers; Tel Aviv Israel
Publisher
Wiley
Subject
Cancer Research,Oncology,Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2350/fullpdf
Reference35 articles.
1. Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies;Korycka-Wolowiec;Expert Opin Drug Metab Toxicol,2012
2. Bendamustine: safety and efficacy in the management of indolent non-Hodgkins lymphoma;Tageja;Clin Med Insights Oncol,2011
3. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents;Leoni;Clin Cancer Res,2008
4. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel;Cheson;Clin Lymphoma Myeloma Leuk,2010
5. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel-an update;Cheson;Leuk Lymphoma,2016
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Signal detection of adverse reactions for bendamustine based on FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-04-30
2. Infection risk and antimicrobial prophylaxis in bendamustine‐treated patients with indolent non‐Hodgkin lymphoma: An Australasian Lymphoma Alliance study;British Journal of Haematology;2024-03-14
3. Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience;Blood Advances;2023-11-15
4. The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study;Leukemia & Lymphoma;2023-07-09
5. Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study;Annals of Hematology;2023-06-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3